OakChart

Starling Oncology Inc

STLNHealthcare·Medical Care Facilities·USA·Small·NASD·Nov 11 • 2:27 PM ET

4.20-0.14 (-3.34%)
2026-11-11 20:28 CET
Market cap
442.64 USD m
Revenue, TTM
620.45 USD m
Net income, TTM
-30.05 USD m
Free cash flow, TTM
18.83 USD m
EPS diluted, TTM
-0.29
P/E
-
Compare

Price

STLN against its 20, 50 and 200-day averages
2050200miss
4.005.006.007.0012.0M23.9MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26STLNclose 4.2020-day 6.1050-day 6.32200-day 4.784.2052w high

41.2% under the 52-week high of 7.13 on 18 Sep 2026. 52-week low 2.32 on 13 Feb 2026. Last 15 sessions, 110.1% high to low

Profile

STLN
52-week range, 39% of the way up
2.327.13

Starling Oncology, Inc. provides cancer care treatment services. It operates through the following business segments: Dispensary, Patient Care, and Clinical Trials and Other. The company was founded in 2007 and is headquartered in Cerritos, CA.

IndexRUT
Employees641
IPOJun 04, 2020
Beta0.46
ATR, 14d0.61
Rel volume1.40
Short float9.57%
Insider own29.95%
Inst own35.39%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap427.85M
Enterprise Value493.68M
Income-30.05M
Sales620.45M
Book/sh-0.37
Cash/sh0.36
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees641
IPOJun 04, 2020

Ratios

P/E-
Forward P/E-
PEG-
P/S0.69
P/B-
P/C11.59
P/FCF22.72
EV/EBITDA-
EV/Sales0.80
Quick Ratio0.82
Current Ratio1.11
Debt/Eq-
LT Debt/Eq-
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.29
EPS next Y-0.09
EPS next Q-0.04
EPS this Y50.93%
EPS next Y67.92%
EPS next 5Y-
EPS past 3/5Y-37.23% -17.58%
Sales past 3/5Y25.81% 21.80%
EPS Y/Y TTM54.77%
Sales Y/Y TTM34.58%
EPS Q/Q10.19%
Sales Q/Q24.31%
EarningsNov 05 AMC
EPS/Sales Surpr.-160.00% 0.65%

Ownership

Insider Own29.95%
Insider Trans-8.96%
Inst Own35.39%
Inst Trans2.63%
ROA-17.11%
ROE-3407.86%
ROIC-56.59%
Gross Margin15.68%
Oper. Margin-3.26%
Profit Margin-4.84%
SMA20-31.21%
SMA50-33.64%
SMA200-12.15%
Trades-

Technical

Shs Outstand101.99M
Shs Float71.45M
Short Float9.57%
Short Ratio3.75
Short Interest6.84M
52W High7.13 -41.16%
52W Low2.32 80.82%
Volatility29.96% 11.40%
ATR (14)0.61
RSI (14)33.31
Beta0.46
Rel Volume1.40
Avg Volume1.82M
Volume1,976,866

Performance

Perf Week-39.55%
Perf Month-37.39%
Perf Quarter-32.99%
Perf Half Y2.82%
Perf YTD17.84%
Perf Year24.85%
Perf 3Y69.84%
Perf 5Y-58.47%
Perf 10Y-
Recom1.00
Target Price9.25
Prev Close4.34
Price4.20
Change %-3.34%

Analyst ratings

latest 8 of 8
DateActionAnalystRating changeTargetImplied
Jul 06, 2026InitiatedLLake StreetBuy$10+138.4%
Nov 25, 2025InitiatedNNeedhamBuy$5+19.2%
Jul 23, 2025InitiatedNNoble Capital MarketsOutperform$8+90.7%
Jul 16, 2025InitiatedRB. Riley SecuritiesBuy$6+43.0%
May 15, 2025InitiatedBBTIG ResearchBuy$7+66.9%
Feb 26, 2024ResumedJJefferiesBuy$2.50-40.4%
Sep 14, 2022InitiatedGGuggenheimBuy$7+66.9%
Aug 15, 2022InitiatedJJefferiesBuy$10+138.4%

Peers

Mkt cap
TickerCompanyMkt cap
ASTHAstrana Health Inc1.64B
AGLAgilon Health Inc1.91B
EVHEvolent Health Inc553.66M
OPCHOption Care Health Inc4.74B
PIIIP3 Health Partners Inc20.47M
AMSAmerican Shared Hospital Services7.85M
CCMConcord Medical Services ADR9.81M
MCKMckesson Corp123.96B
PRVAPrivia Health Group Inc3.07B
CAHCardinal Health Inc63.72B

Insider trading

latest 14 of 33
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Chernett Jorey10% OwnerNov 09 '26Buy3.6548,294176,2737,858,091Nov 10 06:33 PM
Chernett Jorey10% OwnerNov 06 '26Sale3.992,851,06111,375,7337,809,797Nov 10 06:33 PM
Hively BradDirectorAug 21 '26Sale6.51298,8531,946,310411,976Aug 24 05:11 PM
BRADFORD HIVELYDirectorAug 21 '26Proposed Sale6.54298,8531,954,499Aug 21 04:35 PM
Chernett Jorey10% OwnerAug 14 '26Buy6.5412,00078,48010,660,858Aug 17 10:13 AM
Chernett Jorey10% OwnerJul 21 '26Buy5.2718,00094,86010,648,858Jul 22 09:55 AM
Podnos YaleChief Medical OfficerJul 14 '26Option Exercise1.9023,45244,567277,501Jul 16 08:05 PM
Podnos YaleChief Medical OfficerJul 14 '26Sale6.4123,452150,340259,527Jul 16 08:05 PM
YALE PODNOSOfficerJul 14 '26Proposed Sale6.2523,452146,575Jul 14 04:33 PM
Chernett Jorey10% OwnerJul 10 '26Buy5.8515,00087,75010,630,858Jul 13 11:34 AM
Chernett Jorey10% OwnerJun 23 '26Buy5.0218,00090,36010,615,858Jun 24 09:31 AM
Podnos YaleChief Medical OfficerJun 08 '26Sale5.3823,451126,094259,527Jun 09 07:06 PM
YALE PODNOSOfficerJun 08 '26Proposed Sale4.8723,451114,206Jun 08 04:37 PM
Chernett Jorey10% OwnerJun 04 '26Buy4.7512,00057,00010,579,858Jun 05 09:38 AM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
FESMFidelity Enhanced Small Cap Core ETFAUM: 6.82B
XHSState Street SPDR S&P Health Care Services ETFAUM: 246.09M
VHTVanguard Health Care ETFAUM: 21.51B
VFMOVanguard U.S. Momentum Factor ETFAUM: 1.82B
IWCiShares Micro-Cap ETFAUM: 1.22B

News

latest 14 of 200
  • Starling Oncology Misses On GAAP EPS, Beats On EBITDA, But A Capitation Guidance Cut Undercuts The Growth Story (Earnings Whispers) -45.97%
  • Starling Oncology Reports Third Quarter 2026 Financial Results and Updates Full-Year 2026 Guidance (GlobeNewswire)
  • Starling Oncology's Q3 Test: Can Onboarding Costs Stay Contained Ahead Of Its Fourth-Quarter Expansion? (Earnings Whispers)
  • Starling Oncology Announces Third Quarter 2026 Earnings Release Date and Conference Call (GlobeNewswire) -6.26%
  • Starling Oncology Leadership Highlights Recent and Upcoming Industry Conference Participation (GlobeNewswire)
  • Starling Oncology to Participate in Wells Fargo Healthcare Conference (GlobeNewswire) -5.18%
  • Starling Oncology Launches Starling Nexus, a Technology Platform Built to Optimize Oncology Provider Engagement and Accelerate High-Quality Care at Scale (GlobeNewswire)
  • Starling Oncology Reports Second Quarter 2026 Financial Results and Updates Full-Year 2026 Guidance (GlobeNewswire) +28.46%
  • Earnings To Watch: Starling Oncology Inc (STLN) Q2 2026 -- GF Value Sees 44% Downside (GuruFocus.com)
  • The Oncology Institute Rebrands as Starling Oncology (GlobeNewswire) +5.56%
  • The Oncology Institute Announces Second Quarter 2026 Earnings Release Date and Conference Call (GlobeNewswire)
  • The Oncology Institute Completes Strategic Refinancing with OrbiMed, Repaying the Outstanding $86 Million Deerfield Convertible Note, Strengthening its Balance Sheet, and Improving Liquidity (GlobeNewswire) +6.62%
  • The Oncology Institute Chief Medical Officer to Speak on Value-Based Specialty Care at APG Spring Conference (GlobeNewswire)
  • The Oncology Institute to Participate in B. Riley Securities Institutional Investor Conference (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-05-0.130-0.050-0.130169.77168.684
2026Q22026-08-06-0.080-0.064-0.080161.28155.745
2026Q12026-05-07-0.020-0.088-0.021147.44142.14
2025Q42026-03-12-0.060-0.090-0.063141.96139.794
2025Q32025-11-13-0.140-0.113-0.141136.56122.633
2025Q22025-08-13-0.150-0.120-0.150119.8113.323
2025Q12025-05-14-0.210--0.209104.41--
2024Q42025-03-24-0.140--0.143100.27--
2024Q32024-11-13-0.180--0.17599.90--
2024Q22024-08-13-0.170--0.17098.60103.31-
2024Q12024-05-14-0.220-0.120-0.21995.0095.171
2023Q42024-03-27-0.210-0.110-0.20886.0082.041
2023Q32023-11-08-0.190-0.130-0.19482.0474.661
2023Q22023-08-08-0.190-0.170-0.18680.2273.801
2023Q12023-05-10-0.330--0.33476.1965.00-
2022Q42023-03-09-0.160-0.200-0.14871.4264.732

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2021FY-0.160--0.165203-
2022FY-0.210-0.280-0.211252.48245.76
2023FY-0.920-0.510-0.920324320.5
2024FY-0.710--0.706393.41-
2025FY-0.540-0.588-0.560502.73500.58
2026FY--0.265--656.39
2027FY--0.085--875.06
2028FY-0.080--1,131

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-06404177.9176.22181.07
2026Q4S2026-10-21400187.66185.17190.8
2026Q4S2026-10-18430187.66185.17190.8
2026Q4S2026-08-16431187.66185.17190.8
2026Q4S2026-08-07531186.23180.5190.8
2026Q4S2026-08-04501176.91167.8185.17
2026Q4S2026-08-01500178.13167.8191.26
2026Q4S2026-07-06510178.13167.8191.26
2026Q4S2026-07-02510178.14167.8191.26
2026Q4S2026-05-27410180.73172.54191.26
2026Q4S2026-05-18411180.73172.54191.26
2026Q4S2026-05-08411180.12172.54188.82
2026Q4S2026-03-13411178.75171.07183.93
2026Q4S2026-03-06320178.24176.33181.2

Estimate history

EPS, annual--0.242-0.165-0.211-0.92-0.706-0.545-0.2908
Period2019202020212022202320242025TTM
EPS, quarterly-0.175-0.143-0.209-0.15-0.141-0.063-0.021-0.08-0.127
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual0187.515203.003252.483324.239393.412502.729620.45
Period2019202020212022202320242025TTM
Sales, quarterly99.901100.267104.406119.802136.564141.957147.441161.282169.767
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual29.559.1673.24973.26674.14575.73798.863101.991
Period2019202020212022202320242025MRQ
Shares, quarterly75.55975.73788.92893.2897.5798.86399.974100.469101.991
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Total Revenue620.45502.73393.41324.24252.48203.00187.510.00
Cost of Goods Sold Incl. D&A523.14433.24345.70270.54204.80165.50153.810.00
Gross Profit97.3169.4947.7153.7047.6837.5133.700.00
Selling, General and Administrative Excl. Other117.51105.57107.83113.74118.9083.3641.900.00
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-20.20-36.08-60.12-60.04-71.22-45.86-8.20-0.00
Interest Expense7.5211.287.506.784.080.320.350.00
Unusual Expense9.4012.45-3.3215.59-74.71-33.530.00-
Net Income Before Taxes-35.54-60.74-64.66-83.10-0.09-11.60-14.81-0.00
Income Taxes0.00-0.130.00-0.04-0.24-0.67-0.490.00
Consolidated Net Income-30.05-50.30-53.01-67.880.13-10.93-14.32-0.00
Net Income From Continuing Operations-30.05-50.30-53.01-67.880.13-10.93-14.32-0.00
Net Income-30.05-50.30-53.01-67.880.07-10.93-14.32-0.00
EPS (Recurring)-0.22-0.45-0.74-0.77-0.86-0.52-0.24-
EPS (Basic, Before Extraordinaries)-0.29-0.54-0.71-0.920.00-0.17-0.24-
EPS (Diluted)-0.29-0.54-0.71-0.92-0.21-0.17-0.24-
EBITDA-13.59-29.14-53.83-54.16-66.81-42.52-5.02-0.00
Non-Operating Income (Expense)1.59-0.93-0.36-0.700.501.05-6.270.00
Other After Tax Adjustments5.4810.3011.6615.19-0.020.000.000.00
Stock Option Compensation Expense4.563.6011.1514.0721.6617.910.11-
Price To Sales Ratio1.070.650.060.460.533.183.40-
Gross Margin15.6813.8212.1316.5618.8918.4817.97-
Operating Margin-3.26-7.18-15.28-18.52-28.21-22.59-4.37-
Net Margin-4.84-10.01-13.47-20.930.03-5.38-7.64-
Shares Outstanding101.9998.8675.7474.1573.2773.2559.1629.50
Market Capitalization442.64442.6423.35150.45119.36224.25310.50310.50

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue169.77161.28147.44141.96136.56119.80104.41100.27
Cost of Goods Sold Incl. D&A140.62135.96125.74120.82119.37104.1188.9487.34
Gross Profit29.1525.3321.7021.1317.2015.7015.4612.93
Selling, General and Administrative Excl. Other31.3129.9428.2128.0425.2526.9125.3824.86
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-2.16-4.62-6.51-6.91-8.05-11.21-9.91-11.93
Interest Expense1.811.861.931.921.921.875.571.17
Unusual Expense12.393.24-5.16-1.076.134.043.35-0.18
Net Income Before Taxes-15.75-9.79-2.49-7.51-16.50-17.14-19.59-13.18
Income Taxes0.000.000.000.000.00-0.130.000.00
Consolidated Net Income-13.29-8.24-2.09-6.43-13.77-13.99-16.07-10.83
Net Income From Continuing Operations-13.29-8.24-2.09-6.43-13.77-13.99-16.07-10.83
Net Income-13.29-8.24-2.09-6.43-13.77-13.99-16.07-10.83
EPS (Recurring)-0.04-0.06-0.06-0.07-0.10-0.12-0.18-0.14
EPS (Basic, Before Extraordinaries)-0.13-0.08-0.02-0.06-0.14-0.15-0.21-0.14
EPS (Diluted)-0.13-0.08-0.02-0.06-0.14-0.15-0.21-0.14
EBITDA-0.64-2.78-4.90-5.28-6.33-9.41-8.13-10.22
Non-Operating Income (Expense)0.62-0.080.790.25-0.40-0.02-0.75-0.26
Other After Tax Adjustments2.461.550.401.082.733.023.512.36
Stock Option Compensation Expense1.060.851.331.320.810.591.151.29
Price To Sales Ratio1.070.950.570.720.740.450.220.06
Gross Margin17.1715.7014.7214.8912.5913.1014.8112.89
Operating Margin-1.27-2.86-4.42-4.87-5.90-9.36-9.49-11.90
Net Margin-7.83-5.11-1.42-4.53-10.08-11.68-15.40-10.80
Shares Outstanding101.99100.4799.9798.8697.5793.2888.9375.74
Market Capitalization442.64542.91303.44350.24326.33188.4286.3623.35

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Cash & Short Term Investments33.5649.6782.8673.81115.176.000.03
Short Term Receivables59.3248.6842.9140.4321.2417.260.00
Inventories16.8810.0413.689.266.444.350.00
Other Current Assets2.994.034.056.9211.202.110.00
Total Current Assets112.75112.42143.49130.42154.0629.720.03
Net Property, Plant & Equipment33.0637.6740.0533.044.192.100.00
Total Investments and Advances0.000.000.0058.350.000.000.00
Intangible Assets18.2522.0425.1339.3844.8733.740.00
Deferred Tax Assets7.779.1910.188.591.662.12-
Other Assets0.610.590.560.480.320.120.03
Total Assets172.42181.91219.42270.25205.1067.810.05
Short Term Debt Incl. Current Port. of LT Debt7.196.836.405.580.185.370.00
Accounts Payable43.1724.3214.439.3715.5612.640.00
Other Current Liabilities20.6021.0613.9614.7714.0610.600.03
Total Current Liabilities70.9652.2234.7929.7229.8028.610.03
Long Term Debt96.56116.42113.41102.870.006.560.00
Provision for Risks Charges0.000.000.000.000.000.000.00
Deferred Tax Liabilities7.779.2210.218.702.033.73-
Other Liabilities12.860.463.985.7969.110.810.00
Total Liabilities188.14178.32162.39147.08100.9439.710.03
Non-Equity Reserves0.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.00
Common Equity-15.723.5957.02123.17104.1628.100.02
Total Shareholders Equity-15.723.5957.02123.17104.1628.100.02
Accumulated Minority Interest0.000.000.000.000.000.000.00
Total Equity-15.723.5957.02123.17104.1628.100.02
Total Liabilities & Stockholders Equity172.42181.91219.42270.25205.1067.810.05
Book Value Per Share-0.160.050.771.681.420.470.00
Tangible Book Value Per Share-0.34-0.240.431.140.81-0.100.00
Full-Time Employees6418258007506583-
Price to Book Ratio-11.851.512.090.936.861.511.38
Return on Assets-28.39-26.42-27.720.06-5.01-42.21-
Return on Equity--174.89-75.340.12-7.05-101.85-
Return on Invested Capital-62.23-44.17-39.830.06-10.49-41.32-10.13
Quick Ratio1.351.963.734.084.950.890.92
Current Ratio1.592.154.124.395.171.040.92

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Net Income-35.54-60.61-64.66-83.070.15-10.93-14.32-0.00
Depreciation6.616.946.295.874.413.343.18-
Other Funds (Non Cash)18.1727.7813.7838.60-45.52-9.3612.000.00
Funds from Operations-10.76-25.91-44.60-38.67-41.22-18.19-0.48-0.00
Extraordinary Item0.000.000.000.000.000.000.000.00
Changes in Working Capital33.861.3218.062.36-20.54-14.490.990.00
Income Taxes Payable--0.00-0.260.12-1.010.66-
Cash from Operating Activities23.10-24.59-26.54-36.31-61.76-32.680.510.00
Capital Expenditures-4.27-3.20-3.79-4.57-5.53-3.05-1.190.00
Net Assets From Acquisitions0.000.000.00-4.46-8.58-9.11-0.150.00
Sale of Fixed Assets and Businesses-0.130.00-0.000.000.000.000.00
Purchase or Sale of Investments0.000.1350.0071.66-117.510.000.000.00
Purchase of Investments0.000.000.00-9.60-117.510.000.000.00
Sale Or Maturity of Investments-0.1350.0081.260.000.000.000.00
Other Uses0.000.000.000.000.000.00-7.500.00
Other Sources0.000.000.000.000.00-0.000.00
Cash from Investing Activities-4.27-3.0746.2162.64-131.61-12.15-8.840.00
Cash Dividends Paid0.000.000.000.000.000.000.000.00
Change in Capital Stock6.3832.630.07-0.89-8.1420.00-0.290.03
Repurchase of Common Pref Stock0.000.000.00-1.02-9.000.000.000.00
Sale of Common Pref Stock6.3832.630.070.130.8620.00-0.290.03
Proceedsfrom Stock Options3.7429.200.000.000.8620.00-0.340.03
Issuance or Reduction of Debt, Net-9.29-20.04-0.04-0.10109.94-7.2512.180.00
Change in Long Term Debt-14.29-20.04-0.04-0.10109.94-7.2512.180.00
Issuance of Long Term Debt71.620.000.000.00110.000.0012.490.00
Reduction of Long Term Debt-85.92-20.04-0.04-0.10-0.06-7.25-0.310.00
Net Financing Active Other Cash Flow-6.68-1.04-3.53-5.85-9.59141.260.000.00
Other Financing Activities Uses-6.68-1.04-3.53-5.85-9.59-201.110.000.00
Cash from Financing Activities-9.5911.56-3.49-6.8592.21154.0111.890.03
Net Change in Cash9.24-16.1016.1819.48-101.16109.183.550.03
Free Cash Flow18.83-27.79-30.33-40.88-67.28-35.53-0.690.00
Preferred Dividends (Cash Flow)-0.000.000.00-0.000.000.00
Price to Free Cash Flow35.15-------
Deferred Taxes & Investment Tax Credit--0.030.00-0.08-0.26-1.24-1.340.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments36.9041.0930.2833.5627.6630.29
Short Term Receivables60.8066.7159.4559.3259.9855.94
Inventories36.6320.0124.2916.8818.8815.79
Other Current Assets3.361.182.842.993.572.78
Total Current Assets137.69128.99116.86112.75110.09104.79
Net Property, Plant & Equipment32.5731.7733.2233.0633.9834.74
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets16.1016.8217.5318.2518.9619.68
Deferred Tax Assets---7.77--
Other Assets1.420.660.620.610.590.59
Total Assets187.77178.23168.23172.42163.62159.80
Short Term Debt Incl. Current Port. of LT Debt12.277.227.407.197.166.95
Accounts Payable82.0960.2847.6543.1735.6334.93
Other Current Liabilities29.3427.4324.3020.6022.7922.89
Total Current Liabilities123.7094.9479.3570.9665.5864.78
Long Term Debt90.4697.2597.4596.5696.3996.20
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities---7.77--
Other Liabilities10.9710.967.7112.8613.927.80
Total Liabilities225.13203.15184.51188.14175.89168.78
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity-37.35-24.91-16.29-15.72-12.27-8.98
Total Shareholders Equity-37.35-24.91-16.29-15.72-12.27-8.98
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity-37.35-24.91-16.29-15.72-12.27-8.98
Total Liabilities & Stockholders Equity187.77178.23168.23172.42163.62159.80
Book Value Per Share-0.37-0.25-0.16-0.16-0.13-0.10
Tangible Book Value Per Share-0.52-0.42-0.34-0.34-0.32-0.31
Full-Time Employees---641--
Price to Book Ratio-11.85-33.34-19.31-28.30-36.2335.96
Return on Assets-17.11-18.06-21.84-28.37-31.89-31.89
Return on Equity-----3,407.86-535.24
Return on Invested Capital-25.03-11.39-2.58-7.95-16.37-16.04
Quick Ratio0.821.151.171.351.391.37
Current Ratio1.111.361.471.591.681.62

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-15.75-9.79-2.49-7.51-16.50-17.01
Depreciation1.521.841.621.631.721.80
Other Funds (Non Cash)13.395.59-2.271.468.328.32
Funds from Operations-0.84-2.36-3.14-4.42-6.46-6.92
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital10.9814.300.937.65-6.17-3.29
Cash from Operating Activities10.1411.94-2.213.23-12.63-10.20
Capital Expenditures-1.26-0.91-1.04-1.06-0.60-1.21
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.00-0.130.000.00
Purchase or Sale of Investments0.000.000.000.130.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments---0.130.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-1.26-0.91-1.04-1.06-0.60-1.21
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock1.960.090.244.0910.842.20
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock1.960.090.244.0910.842.20
Proceedsfrom Stock Options-0.220.000.223.7410.100.00
Issuance or Reduction of Debt, Net-9.26-0.01-0.01-0.01-0.01-0.01
Change in Long Term Debt-14.26-0.01-0.01-0.01-0.01-0.01
Issuance of Long Term Debt71.620.000.000.000.000.00
Reduction of Long Term Debt-85.89-0.01-0.01-0.01-0.01-0.01
Net Financing Active Other Cash Flow-5.77-0.30-0.26-0.35-0.23-0.23
Other Financing Activities Uses-5.77-0.30-0.26-0.35-0.23-0.23
Cash from Financing Activities-13.08-0.22-0.033.7310.601.96
Net Change in Cash-4.2010.81-3.295.91-2.63-9.45
Free Cash Flow8.8811.03-3.262.17-13.23-11.41
Price to Free Cash Flow35.15-----

Revenue breakdown

Capitated2024: 68.69M 2025: 80.48M
Clinical Research Trials And Other2024: 8.61M 2025: 4.56M
Fee For Service2024: 136.20M 2025: 148.51M
Health Care, Specialty Pharmacy2024: 179.92M 2025: 269.18M
United States2024: 393.41M 2025: 502.73M
Clinical Trials And Other,2024: 8.61M 2025: 4.56M
Patient Services,2024: 204.88M 2025: 228.99M
Specialty pharmacy,2024: 179.92M 2025: 269.18M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-309.77%6.8M70.0M1.36M
2026-10-159.33%6.5M70.0M1.41M
2026-09-309.70%6.8M70.0M1.60M
2026-09-1511.10%7.1M63.6M1.67M
2026-08-3110.72%6.8M63.6M1.84M
2026-08-1410.88%6.9M63.3M1.92M
2026-07-1511.45%7.3M63.5M1.88M
2026-06-3010.77%6.8M63.6M1.71M
2026-06-1510.52%6.7M63.6M1.82M
2026-05-2911.14%6.4M57.6M1.87M
2026-05-1511.21%6.5M58.2M1.81M
2026-04-3012.76%7.3M57.4M1.82M
2026-04-1514.22%8.1M56.8M1.92M
2026-03-3112.80%8.3M64.8M2.11M
2026-03-1313.86%9.0M64.8M1.85M
2026-02-2714.08%9.1M64.5M1.77M
2026-02-1314.00%9.0M64.5M2.19M
2026-01-3012.74%8.2M64.5M2.25M
2026-01-1510.77%6.9M64.5M2.34M
2025-12-318.34%5.8M69.6M2.20M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call1.002.953.900.0017.5644.000.000.977-0.0120.000
call2.001.952.954.409.63817.000.000.954-0.0120.001
call3.000.951.951.145.9031380.000.915-0.0100.001
call4.000.300.450.351.35313,73820.000.646-0.0140.002
call5.000.000.100.051.2937,7353200.225-0.0140.002
call6.000.000.050.051.58120,8280.000.108-0.0110.001
call7.000.000.100.042.10813,7652.000.088-0.0130.001
call8.000.000.050.152.3142,0750.000.078-0.0120.001
call9.000.000.050.052.6341,1530.000.071-0.0130.001
call10.000.000.700.003.1600.000.000.066-0.0150.001
call11.000.000.700.003.4230.000.000.062-0.0150.001
call12.500.000.700.003.7530.000.000.058-0.0160.001
put1.000.002.150.006.0690.000.00-0.023-0.0120.000
put2.000.002.150.023.35210.000.00-0.044-0.0120.001
put3.000.000.050.052.1871,2050.00-0.113-0.0150.001
put4.000.050.150.080.93458232.00-0.349-0.0140.002
put5.000.500.900.661.3183820.00-0.775-0.0140.002
put6.001.052.502.504.63947.000.00-0.894-0.0110.001
put7.002.054.600.819.6373.000.00-0.912-0.0120.001
put8.003.105.704.5010.57623.000.00-0.923-0.0130.001
put9.004.006.700.0011.0150.000.00-0.929-0.0130.001
put10.005.007.700.0011.3650.000.00-0.934-0.0140.001
put11.006.108.700.0011.6990.000.00-0.938-0.0140.001
put12.507.6010.200.0012.1570.000.00-0.942-0.0150.001

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-104Statement of changes in beneficial ownership of securities2026-11-06SEC
2026-11-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-058-KCurrent report2026-11-05SEC
2026-09-028-KCurrent report2026-09-01SEC
2026-08-244Statement of changes in beneficial ownership of securities2026-08-21SEC
2026-08-21144Filing for proposed sale of securities under Rule 144.SEC
2026-08-218-KCurrent report2026-08-20SEC
2026-08-174Statement of changes in beneficial ownership of securities2026-08-13SEC
2026-08-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-068-KCurrent report2026-08-06SEC
2026-08-038-KCurrent report2026-07-28SEC
2026-07-294Statement of changes in beneficial ownership of securities2026-07-27SEC
2026-07-294Statement of changes in beneficial ownership of securities2026-07-27SEC
2026-07-294Statement of changes in beneficial ownership of securities2026-07-27SEC
2026-07-294Statement of changes in beneficial ownership of securities2026-07-27SEC
2026-07-294Statement of changes in beneficial ownership of securities2026-07-27SEC
2026-07-294Statement of changes in beneficial ownership of securities2026-07-27SEC
2026-07-294Statement of changes in beneficial ownership of securities2026-07-27SEC
2026-07-224Statement of changes in beneficial ownership of securities2026-07-21SEC
2026-07-164Statement of changes in beneficial ownership of securities2026-07-14SEC
2026-07-14144Filing for proposed sale of securities under Rule 144.SEC
2026-07-134Statement of changes in beneficial ownership of securities2026-07-10SEC
2026-07-094Statement of changes in beneficial ownership of securities2026-07-07SEC
2026-07-094Statement of changes in beneficial ownership of securities2026-07-07SEC
2026-07-078-KCurrent report2026-07-01SEC
2026-06-244Statement of changes in beneficial ownership of securities2026-06-23SEC
2026-06-188-KCurrent report2026-06-17SEC
2026-06-094Statement of changes in beneficial ownership of securities2026-06-08SEC
2026-06-08144Filing for proposed sale of securities under Rule 144.SEC
2026-06-054Statement of changes in beneficial ownership of securities2026-06-04SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-11176.27K111.38M1
2026-100000
2026-090000
2026-0878.48K11.95M1
2026-07182.61K2150.34K1
2026-06147.36K2126.09K1
2026-05279.30K300
2026-0462.00K1335.13K2
2026-031.94M700
2026-020000
2026-01008791
2025-120050.29K1
2025-1100200.00K1

Institutional holders

Manager% owned
BlackRock, Inc.4.75%
DEERFIELD MANAGEMENT COMPANY, L.P.3.36%
VANGUARD CAPITAL MANAGEMENT LLC3.27%
JOSH ARNOLD INVESTMENT CONSULTANT, LLC2.46%
GEODE CAPITAL MANAGEMENT, LLC2.11%
GOLDMAN SACHS GROUP INC1.74%
WEXFORD CAPITAL LP1.71%
STATE STREET CORP1.55%
RENAISSANCE TECHNOLOGIES LLC1.37%
CenterBook Partners LP1.24%

Funds

Fund% owned
Akre Focus ETF5.29%
Inspire Fidelis Multi Factor ETF0.46%
VANGUARD RUSSELL 2000 INDEX FUND0.44%
Invesco Dorsey Wright SmallCap Momentum ETF0.32%
VANGUARD U.S. MOMENTUM FACTOR ETF0.32%
VANGUARD HEALTH CARE INDEX FUND0.20%
SMALLCAP World Fund Inc0.18%
Goldman Sachs Small Cap Equity Insights Fund0.16%
Pabrai Wagons ETF0.15%
Goldman Sachs ActiveBeta(R) U.S. Small Cap Equity ETF0.13%

OakChart. STLN. Cached 15 minutes.